Nov. 13, 2021 – About 29.1% of patients who received the highest dose of psilocybin — the compound found in magic mushrooms — were in remission three weeks after treatment compared with 7.6% of those in the control group, according to Compass Pathways.
The patients that received 25-milligram — the highest dose of the drug in the study — also experienced a “highly statistically significant and clinically relevant reduction in depressive symptom severity after three weeks,” per Compass Pathways.
Patients who received the lower 10-milligram dose did not experience a statistically significant difference after three weeks.
The big picture: The results of the study, which included 233 patients across Europe and North America, come after the Food and Drug Administration granted Compass Pathways a breakthrough therapy designation, paving the way for a potentially accelerated drug approval process, per Stat.
Between the lines: The study also included data on patients who experienced adverse side effects from the drug.
Twelve patients reported treatment-emergent serious adverse events, including five who were in the 25-milligram group and six in the 10-milligram group.
EMR MATTERS – October 2024 - The challenge is that many in the behavioral health…
TOO LITTLE, TOO LATE? – Dec. 19, 2024 - Assembly Bill 56 (AB 56) proposes…
AND STOPPED DIGGING – Dec. 4, 2024 - In a new interview with The Times,…
NOT JUST IN PENCILS – Dec. 8, 2024 - Americans born before 1966 experienced “significantly…
AS SUCCESSFUL AS EVER – Dec. 3, 2024 - Family Affair actor Johnny Whitaker looked…
ALANON Plus – Dec. 7, 2024 - A high percentage of treatment failures occur due…